Dynamic Changes of Matrix Metalloproteinase-9 in Patients with Klebsiella pneumoniae Meningitis
To quantitate cerebrospinal fluid (CSF) concentrations of matrix metalloproteinase 9 (MMP-9) in adult patients with Klebsiella pneumoniae meningitis and to correlate levels of MMP-9 with parameters of intrathecal inflammation and analyze the kinetic changes of MMP-9. In a prospective cohort study, levels of MMP-9 and tissue inhibitor of matrix metalloproteinase (TIMP-1) concentrations were measured in the CSF of six adult patients with meningitis and 11 controls. MMP-9 and TIMP-1 were detected in all of the six patients at presentation and follow up lumbar puncture. CSF levels of MMP-9 (6.71 ± 7.29 ng/ml) and TIMP-1(454.3 ± 242.9 ng/ml) were higher in patients than in the control group (0.07 ± 0.11 ng/ml and 27.14 ± 39.34 ng/ml, respectively). Levels of MMP-9 correlated with CSF concentrations of protein, cell count and lactate. Repeated lumbar punctures showed that levels of MMP-9 decrease during clinical recovery, although the levels of MMP-9 in the CSF are variable because of the small number of cases. The relative change in gelatin zymography is comparable to the changes of MMP-9 levels found in ELISA. MMP-9 levels in CSF may be a useful tool in follow-up in patients with K. pneumoniae meningitis.
KEY WORDSgelatin zymography Klebsiella pneumoniae matrix metalloproteinase 9 meningitis
This work is supported by the Summer Medical Student Research Program 2007, from the Medical Foundation in Memory of Dr. Deh-Lin Cheng and also supported by grant VGHKS96-027 from Kaohsiung Veterans General Hospital, and grant NSC-96-2320-B-075B-002 from the National Science Council, Republic of China.
- 3.Lee, P. Y., W. N. Chang, C. H. Lu, M. W. Lin, B. C. Cheng, C. C. Chien, C. J. Chang, and H. W. Chang. 2003. Clinical features and in vitro antimicrobial susceptibilities of community-acquired Klebsiella pneumoniae meningitis in Taiwan. J. Antimicrob. Chemother. 51:957–62.PubMedCrossRefGoogle Scholar
- 7.Täuber, M. G., Y. S. Kim, and S. L. Leib. 1997. Neuronal injury in meningitis. In: In defense of the brain, Peterson, P. K., and J. S. Remington eds. Blackwell, Malden, MA, pp. 124–143.Google Scholar
- 9.Leppert, D., S. L. Leib, C. Grygar, K. M. Miller, U. B. Schaad, and G. A. Holländer. 2000. Matrix metalloproteinase (MMP)-8 and MMP-9 in cerebrospinal fluid during bacterial meningitis: association with blood–brain barrier damage and neurological sequelae. Clin. Infect. Dis. 31:80–84.PubMedCrossRefGoogle Scholar
- 15.Leib, S. L., J. M. Clements, R. L. Lindberg, C. Heimgartner, J. M. Loeffler, L. A. Pfister, M. G. Tauber, and D. Leppert. 2001. Inhibition of matrix metalloproteinases and tumour necrosis factor alpha converting enzyme as adjuvant therapy in pneumococcal meningitis. Brain. 124:1734–1742.PubMedCrossRefGoogle Scholar
- 17.Lee, H. C., Y. C. Chuang, W. L. Yu, N. Y. Lee, C. M. Chang, N. Y. Ko, L. R. Wang, and W. C. Ko. 2006. Clinical implications of hypermucoviscosity phenotype in Klebsiella pneumoniae isolates: association with invasive syndrome in patients with community-acquired bacteraemia. J. Intern, Med. 259:606–614.CrossRefGoogle Scholar
- 25.Miller, A., S. Shapiro, N. Lahat, and Y. Galboiz. 2002. Matrix metalloproteinases and their inhibitors in brain injury and repair. In: Brain disease: therapeutic strategies and repair, Abramsky, O., D. A. S. Comspton, A. Miller, and G. Said eds. Martin Dunitz, UK, pp. 63–68.Google Scholar